195 related articles for article (PubMed ID: 33733815)
21. Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis.
Vazquez R; Breal C; Zalmai L; Friedrich C; Almire C; Contejean A; Barreau S; Grignano E; Willems L; Deau-Fischer B; Franchi P; Vignon M; Decroocq J; Birsen R; Goldwirt L; Kaltenbach S; Couronne L; Fontenay M; Kosmider O; Bouscary D; Chapuis N
Blood Cancer J; 2021 Mar; 11(3):62. PubMed ID: 33741892
[No Abstract] [Full Text] [Related]
22. Mechanisms for resistance in AML insights into molecular pathways mediating resistance to venetoclax.
Konopleva MY
Best Pract Res Clin Haematol; 2021 Mar; 34(1):101251. PubMed ID: 33762105
[TBL] [Abstract][Full Text] [Related]
23. Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations.
Walter RB; Ofran Y; Wierzbowska A; Ravandi F; Hourigan CS; Ngai LL; Venditti A; Buccisano F; Ossenkoppele GJ; Roboz GJ
Leukemia; 2021 Jun; 35(6):1529-1538. PubMed ID: 33758317
[TBL] [Abstract][Full Text] [Related]
24. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
Thijssen R; Diepstraten ST; Moujalled D; Chew E; Flensburg C; Shi MX; Dengler MA; Litalien V; MacRaild S; Chen M; Anstee NS; Reljić B; Gabriel SS; Djajawi TM; Riffkin CD; Aubrey BJ; Chang C; Tai L; Xu Z; Morley T; Pomilio G; Bruedigam C; Kallies A; Stroud DA; Bajel A; Kluck RM; Lane SW; Schoumacher M; Banquet S; Majewski IJ; Strasser A; Roberts AW; Huang DCS; Brown FC; Kelly GL; Wei AH
Blood; 2021 May; 137(20):2721-2735. PubMed ID: 33824975
[TBL] [Abstract][Full Text] [Related]
25. Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.
Apel A; Moshe Y; Ofran Y; Gural A; Wolach O; Ganzel C; Canaani J; Zektser M; Duek A; Stemer G; Hellman I; Basood M; Frisch A; Leibovitch C; Koren-Michowitz M
Am J Hematol; 2021 Jul; 96(7):790-795. PubMed ID: 33836555
[TBL] [Abstract][Full Text] [Related]
26. Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial.
Bouvier A; Hamel JF; Delaunay J; Delabesse E; Dumas PY; Ledoux MP; Peterlin P; Luquet I; Roth Guepin G; Bulabois CE; Gallego Hernanz MP; Guillerm G; Guieze R; Hicheri Y; Simand C; Himberlin C; Hunault-Berger M; Bernard M; Jourdan E; Caillot D; Dorvaux V; Tavernier E; Daguindau E; Banos A; Ojeda-Uribe M; Gyan E; Alexis M; Marolleau JP; Turlure P; Bouscary D; Humbrecht C; Zerazhi H; Béné MC; Pigneux A; Carre M; Ifrah N; Blanchet O; Vey N; Récher C; Cornillet-Lefèbvre P;
Eur J Haematol; 2021 Jul; 107(1):111-121. PubMed ID: 33765335
[TBL] [Abstract][Full Text] [Related]
27. Perspectives on current survival and new developments in AML.
Rowe JM
Best Pract Res Clin Haematol; 2021 Mar; 34(1):101248. PubMed ID: 33762103
[TBL] [Abstract][Full Text] [Related]
28. Immune checkpoint inhibitors in acute myeloid leukemia.
Daver N
Best Pract Res Clin Haematol; 2021 Mar; 34(1):101247. PubMed ID: 33762102
[TBL] [Abstract][Full Text] [Related]
29. Emerging agents and regimens for AML.
Liu H
J Hematol Oncol; 2021 Mar; 14(1):49. PubMed ID: 33757574
[TBL] [Abstract][Full Text] [Related]
30. Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience.
Piccini M; Pilerci S; Merlini M; Grieco P; Scappini B; Bencini S; Peruzzi B; Caporale R; Signori L; Pancani F; Vannucchi AM; Gianfaldoni G
J Clin Med; 2021 Apr; 10(8):. PubMed ID: 33919958
[TBL] [Abstract][Full Text] [Related]
31. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs.
Masarova L; DiNardo CD; Bose P; Pemmaraju N; Daver NG; Kadia TM; Chifotides HT; Zhou L; Borthakur G; Estrov Z; Konopleva M; Verstovsek S
Blood Adv; 2021 Apr; 5(8):2156-2164. PubMed ID: 33885751
[TBL] [Abstract][Full Text] [Related]
32. Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
Heuser M; Smith BD; Fiedler W; Sekeres MA; Montesinos P; Leber B; Merchant A; Papayannidis C; Pérez-Simón JA; Hoang CJ; O'Brien T; Ma WW; Zeremski M; O'Connell A; Chan G; Cortes JE
Ann Hematol; 2021 Jul; 100(7):1917-1918. PubMed ID: 33978823
[No Abstract] [Full Text] [Related]
33. Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review.
Chang Y; Guyatt GH; Teich T; Dawdy JL; Shahid S; Altman JK; Stone RM; Sekeres MA; Mukherjee S; LeBlanc TW; Abel GA; Hourigan CS; Litzow MR; Michaelis LC; Alibhai SMH; Desai P; Buckstein R; MacEachern J; Brignardello-Petersen R
PLoS One; 2021; 16(3):e0249087. PubMed ID: 33784346
[TBL] [Abstract][Full Text] [Related]
34. Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD
Liu Y; Wei J; Liu J; Ma W; Duan Y; Liu D
Oncol Lett; 2021 May; 21(5):397. PubMed ID: 33777220
[TBL] [Abstract][Full Text] [Related]
35. Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant.
DiNardo CD; Stein EM; Pigneux A; Altman JK; Collins R; Erba HP; Watts JM; Uy GL; Winkler T; Wang H; Choe S; Liu H; Wu B; Kapsalis SM; Roboz GJ; de Botton S
Leukemia; 2021 Nov; 35(11):3278-3281. PubMed ID: 33772143
[No Abstract] [Full Text] [Related]
36. The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes.
Kipp D; H Wei A
Future Oncol; 2021 Jul; 17(20):2563-2571. PubMed ID: 33769069
[TBL] [Abstract][Full Text] [Related]
37. Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
Daher-Reyes G; Kim T; Novitzky-Basso I; Kim KH; Smith A; Stockley T; Capochichi JM; Al-Shaibani Z; Pasic I; Law A; Lam W; Michelis FV; Gerbitz A; Viswabandya A; Lipton J; Kumar R; Mattsson J; Schimmer A; McNamara C; Murphy T; Maze D; Gupta V; Sibai H; Chan S; Yee K; Minden M; Zhang Z; Schuh A; Kim DDH
Bone Marrow Transplant; 2021 Aug; 56(8):1908-1918. PubMed ID: 33767401
[TBL] [Abstract][Full Text] [Related]
38. Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?
Bewersdorf JP; Zeidan AM
Best Pract Res Clin Haematol; 2021 Mar; 34(1):101245. PubMed ID: 33762100
[TBL] [Abstract][Full Text] [Related]
39. Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches.
Grieselhuber NR; Mims AS
Curr Hematol Malig Rep; 2021 Apr; 16(2):192-206. PubMed ID: 33738705
[TBL] [Abstract][Full Text] [Related]
40. TKI Maintenance After Stem-Cell Transplantation for
Gagelmann N; Wolschke C; Klyuchnikov E; Christopeit M; Ayuk F; Kröger N
Front Immunol; 2021; 12():630429. PubMed ID: 33790903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
